ASMS understated Huwel investment by 87.5%, blames error
The nano-cap said its stake in molecular diagnostics firm Huwel Lifesciences is ₹7.50 cr, not ₹4 cr as originally disclosed. The sharp upward revision is 3.45% of ASMS's market cap.
— 3 earlier stories on Avio Smart Market Stack Ltd. →What's new
- ASMS revised its investment in Huwel Lifesciences from ₹4 cr to ₹7.50 cr, an 87.5% increase.
- The correction is attributed to an 'inadvertent error' in the earlier intimation.
- The revised investment gives ASMS a 2.06% stake in Huwel, which had FY25 turnover of ₹15.74 cr.
Why this matters
For a ₹217 cr nano-cap, an 87.5% swing in disclosed investment is material — 3.45% of market cap. The revision signals either poor disclosure controls or a deliberate understatement. Either way, it changes the perceived commitment to Huwel and warrants scrutiny of the company's governance.
What we're watching
- Any formal explanation from ASMS on how the error occurred.
- Whether the higher cash outlay strains ASMS's cash flows (Mar qtr net profit was ₹2 cr).
- Updates from Huwel's performance to justify the stepped-up investment.
The full read
Avio Smart Market Stack (ASMS) said its investment in Huwel Lifesciences is ₹7.50 crore, not the ₹4 crore it disclosed in April 2026. The company blames an inadvertent error. That is a costly mistake. For a nano-cap with a ₹217 crore market cap, an 87.5% understatement is far from trivial, it exceeds the ₹5 crore automatic materiality threshold and represents 3.45% of the entire valuation. The stake remains a minority 2.06% in Huwel, a diagnostics firm with ₹15.74 crore in FY25 turnover, but the higher cash outlay comes when ASMS's latest quarterly net profit was just ₹2 crore. The core investment event was already public, yet a revision of this magnitude naturally raises questions about disclosure discipline; the burden is now on ASMS to show this was a one-off lapse, not a pattern.
Questions answered
- What exactly did ASMS revise about its Huwel investment?
- ASMS said the investment value is ₹7.50 crore, not the ₹4 crore it disclosed in April 2026. The equity stake remains at 2.06%.
- Why did ASMS give a wrong figure initially?
- The company cited an inadvertent error in the earlier intimation. No further details were provided.
- How material is the 87.5% increase for ASMS?
- The ₹3.50 crore difference is about 3.45% of ASMS's ₹217 crore market cap. Given ASMS posted a net profit of ₹2 crore in the March 2026 quarter, the extra outlay is significant.
- What does Huwel Lifesciences do, and how is ASMS's stake valued?
- Huwel is a molecular diagnostics and medical devices company with FY25 turnover of ₹15.74 crore. ASMS's ₹7.50 crore investment buys a 2.06% minority stake.
- Does this revision change the nature of the investment?
- No. The terms, including cash consideration and arm's-length nature, remain unchanged. Only the quantum was revised.
Avio Smart Market Stack Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ASMS →- 15 Jul 2026 · 4:50 PM IST ASMS understated Huwel investment by 87.5%, blames error
- 1d ago Avio Smart Market lands Tripura MoU for freeze-drying facility
- 14d ago Avio Smart Market ties up with Intellecap to digitize farmer collectives
- 14d ago Avio Smart Market inks AI MoU with StandardWings for rural digital infra